http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I750403-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8905c7ab90ee87f76b7f64464c95a3a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2018-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4240ae3b7ec59690ec54024046a455c |
| publicationDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I750403-B |
| titleOfInvention | Fibroblast growth factor receptor inhibitors, pharmaceutical preparations containing them, and uses thereof |
| abstract | The invention belongs to the technical field of medicine, and particularly relates to an irreversible inhibitor of fibroblast growth factor receptor (FGFR) represented by formula I, a pharmaceutically acceptable salt and a stereoisomer thereof. The present invention also relates to pharmaceutical formulations, pharmaceutical compositions and uses of these compounds. R 1 , R 2 , R 3 , R 4 , m, X, warhead 1 , warhead 2 are as defined in the specification. The compounds of the present invention have efficient and highly selective inhibitory effects on fibroblast growth factor receptors, and can be applied to the treatment of related diseases mediated by abnormal FGF/FGFR, especially the treatment of cancer diseases. |
| priorityDate | 2017-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.